DEMOGRAPHIC, CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES BY LINES OF TREATMENT IN HR+/HER2− ADVANCED BREAST CANCER IN COLOMBIA
Author(s)
Franco S1, Lobaton JF2, Aruachan S3, Montoya ME4, Rojas G5, Londoño PA5, Kurosky S6, Matiz GA7, Alarcon BA7, Castaño Gamboa N7, Reyes Sanchez JM8
1Clínica del Country, Bogotá, Colombia, 2Instituto Medico de alta tecnología Oncomedica, Monteria, Colombia, 3Instituto Medico de alta tecnología Oncomedica,, Monteria, Colombia, 4Instituto de Cancerología, Medellín, Colombia, 5Oncólogos de Occidente, Pereira, Colombia, 6RTI Health Solutions, Research Triangle Park, NY, USA, 7Pfizer SAS, Bogotá, Colombia, 8Pfizer SAS, Bogota, CUN, Colombia
OBJECTIVES: To describe characteristics, treatment patterns, and clinical outcomes by treatment line among patients with hormonal receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC). METHODS: A retrospective study was performed using medical records of patients who initiated first-line treatment for advanced HR+/HER2- BC in four hospitals from 2012 through 2014. The Kaplan-Meier method was used to calcu¿late time to progression (TTP) and overall survival (OS) from the start of first- and second-line therapy. RESULTS: 145 patients were followed for a mean of 31.0 (SD 17.8) months after advanced diagnosis; 25 patients were lost and 44.8% of patients died. The mean age was 57.6 (SD 12.0) years. At initial diagnosis, 32.4% of patients were in early stages; 17.9% in IIIA stage; 62.7% advanced stage. Most frequently received first-line treatments were endocrine therapy alone (48.3%) and chemotherapy alone (24.1%), and for second-line, endocrine therapy (46.7%) and chemotherapy (41.3). For first-line therapy, median TTP was 13.3 [95% confidence interval (CI), 9.8, 19.7] months for patients treated with endocrine therapy alone, 4.9 [95%CI, 2.9-11.5] months for patients who received chemotherapy; and 25.0 [95%CI, 18.5-30.8] months for patients with chemotherapy followed by endocrine therapy. For second-line therapy (92 patients), the median TTP for patients treated with endocrine therapy was 7.6 [95%CI, 4.2-10.0] months and 5.8 [95%CI, 4.2-10.4] months for patients with chemotherapy. Median OS from advanced diagnosis was 3.6 (95%CI, 2.8-5.1; 57.1% censored) years among patients who received endocrine therapy alone and 2.0 (95%CI, 1.2-3.3; 40.0% censored) years on chemotherapy alone. CONCLUSIONS: Patients were diagnosed mainly in advanced stages; endocrine and chemotherapy were the most commonly used therapy. Patients who were prescribed endocrine therapy demonstrated longer TTP and OS than patients who received chemotherapy in the first- and second-line therapies. This study was limited by the small sample and potential selection.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PCN358
Topic
Clinical Outcomes, Health Service Delivery & Process of Care
Topic Subcategory
Clinical Outcomes Assessment, Disease Management
Disease
Oncology